Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- The study was conducted between 16 July 2018 and 23 July 2018.
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 019
- Report date:
- 2019
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- yes
- Remarks:
- This deviation is considered to have no impact on either the result or integrity of the study.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- yes
- Remarks:
- This deviation is considered to have no impact on either the result or integrity of the study.
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5100 - Bacterial Reverse Mutation Test (August 1998)
- Deviations:
- yes
- Remarks:
- This deviation is considered to have no impact on either the result or integrity of the study.
- Qualifier:
- according to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- Deviations:
- yes
- Remarks:
- This deviation is considered to have no impact on either the result or integrity of the study.
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
Test material
- Reference substance name:
- Silicon
- EC Number:
- 231-130-8
- EC Name:
- Silicon
- Cas Number:
- 7440-21-3
- Molecular formula:
- Si
- IUPAC Name:
- Silicon
- Reference substance name:
- Magnesium silicate
- EC Number:
- 237-413-2
- EC Name:
- Magnesium silicate
- Cas Number:
- 13776-74-4
- Molecular formula:
- H2O3Si.Mg
- IUPAC Name:
- magnesium(2+) ion oxosilanebis(olate), crystalline
- Reference substance name:
- Silicon dioxide
- EC Number:
- 231-545-4
- EC Name:
- Silicon dioxide
- Cas Number:
- 7631-86-9
- Molecular formula:
- O2Si
- IUPAC Name:
- Silicon dioxide, amorphous
- Reference substance name:
- Dimagnesium silicate
- EC Number:
- 233-112-5
- EC Name:
- Dimagnesium silicate
- Cas Number:
- 10034-94-3
- Molecular formula:
- Mg2O4Si
- IUPAC Name:
- dimagnesium silicate
- Reference substance name:
- Carbon
- EC Number:
- 231-153-3
- EC Name:
- Carbon
- Cas Number:
- 7440-44-0
- Molecular formula:
- C
- IUPAC Name:
- Carbon
- Reference substance name:
- Metallic impurities (Na and S)
- IUPAC Name:
- Metallic impurities (Na and S)
- Test material form:
- solid: particulate/powder
Constituent 1
Constituent 2
Constituent 3
Constituent 4
impurity 1
impurity 2
- Specific details on test material used for the study:
- Identification: Reaction mass of crystalline magnesium silicate and crystalline silicon and synthetic amorphous silicon dioxide
Chemical Name: Reaction mass of Magnesium dioxido(oxo)silane and Silicone dioxide (MgSiO3, Si and SiO2)
Physical state/Appearance: Black powder
Batch Number: Y180510A
Purity: > 95%
Expiry Date: 31 May 2019
Storage Conditions: Room temperature in the dark
Method
- Target gene:
- Salmonella typhimurium: histidine
Escherichia coli (WP2uvrA): tryptophan
Species / strainopen allclose all
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver homogenate metabolizing system (10% liver S9 in standard co-factors)
- Test concentrations with justification for top dose:
- Test for Mutagenicity: Experiment 1 – Plate Incorporation Method
The maximum concentration was 5000 µg/plate (the OECD TG 471 maximum recommended dose level)
Eight concentrations of the test item (1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate) were assayed in triplicate against each tester strain, using the direct plate incorporation method.
Test for Mutagenicity: Experiment 2 – Pre-Incubation Method
The dose range used for Experiment 2 was determined by the results of Experiment 1 and was 15, 50, 150, 500, 1500 and 5000 µg/plate.
Six test item concentrations per bacterial strain were selected in Experiment 2 in order to achieve both four non toxic dose levels and the potential toxicity of the test item following the change in test methodology from plate incorporation to pre-incubation. - Vehicle / solvent:
- Vehicle: DMSO
The test item was insoluble in sterile distilled water, dimethyl sulphoxide, dimethyl formamide and acetonitrile at 50 mg/mL, acetone at 100 mg/mL and tetrahydrofuran at 200 mg/mL in solubility checks performed in–house. The test item formed the best doseable suspension in dimethyl sulphoxide, therefore, this solvent was selected as the vehicle.
Controlsopen allclose all
- Untreated negative controls:
- yes
- Remarks:
- Untreated plates
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO (> 99.9%)
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- 9-aminoacridine
- N-ethyl-N-nitro-N-nitrosoguanidine
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- yes
- Remarks:
- Untreated plates
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO (> 99.9%)
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- other: 2-Aminoanthracene
- Remarks:
- Presence of S9-mix
- Details on test system and experimental conditions:
- Microsomal Enzyme Fraction
The S9 Microsomal fractions (CD Sprague-Dawley) were pre-prepared using standardized in house procedures (outside the confines of this study). Lot No. PB/βNF S9 25 May 2018 was used in this study.
S9-Mix and Agar
The S9-mix was prepared before use using sterilized co-factors and maintained on ice for the duration of the test.
S9 5.0 mL
1.65 M KCl/0.4 M MgCl2 1.0 mL
0.1 M Glucose-6-phosphate 2.5 mL
0.1 M NADP 2.0 mL
0.2 M Sodium phosphate buffer (pH 7.4) 25.0 mL
Sterile distilled water 14.5 mL
A 0.5 mL aliquot of S9-mix and 2 mL of molten, trace histidine or tryptophan supplemented, top agar were overlaid onto a sterile Vogel-Bonner Minimal agar plate in order to assess the sterility of the S9-mix. This procedure was repeated, in triplicate, on the day of each experiment.
Media
Top agar was prepared using 0.6% Bacto agar (lot number 7193746 04/2022) and 0.5% sodium chloride with 5 mL of 1.0 mM histidine and 1.0 mM biotin or 1.0 mM tryptophan solution added to each 100 mL of top agar. Vogel-Bonner Minimal agar plates were purchased from SGL Ltd (lot numbers 48097 08/2018 and 48043 08/2018).
Test Item Preparation and Analysis
The test item was accurately weighed and, on the day of each experiment, approximate half log dilutions prepared in pre-dried dimethyl sulphoxide by mixing on a vortex mixer and sonication for 20 minutes at 40 °C. Formulated concentrations were adjusted to allow for the stated water/impurity content (95%) of the test item.
All formulations were used within four hours of preparation and were assumed to be stable for this period. Analysis for concentration, homogeneity and stability of the test item formulations is not a requirement of the test guidelines and was, therefore, not determined. This is an exception with regard to GLP and has been reflected in the GLP compliance statement.
Test for Mutagenicity: Experiment 1 – Plate Incorporation Method
Without Metabolic Activation
A 0.1 mL aliquot of the appropriate concentration of test item, solvent vehicle or 0.1 mL of the appropriate positive control was added together with 0.1 mL of the bacterial strain culture, 0.5 mL of phosphate buffer and 2 mL of molten, trace amino-acid supplemented media. These were then mixed and overlayed onto a Vogel Bonner agar plate. Negative (untreated) controls were also performed on the same day as the mutation test. Each concentration of the test item, appropriate positive, vehicle and negative controls, and each bacterial strain, was assayed using triplicate plates.
With Metabolic Activation
The procedure was the same as described previously except that following the addition of the test item formulation and bacterial culture, 0.5 mL of S9 mix was added to the molten, trace amino-acid supplemented media instead of phosphate buffer.
Incubation and Scoring
All of the plates were incubated at 37 ± 3 °C for between 48 and 72 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity). Manual counts were performed on various plates due to spreading colonies/artefact , thereby obtaining an accurate count for reporting.
Test for Mutagenicity: Experiment 2 – Pre-Incubation Method
As the result of Experiment 1 was considered negative, Experiment 2 was performed using the pre-incubation method in the presence and absence of metabolic activation (S9-mix).
Without Metabolic Activation
A 0.1 mL aliquot of the appropriate bacterial strain culture, 0.5 mL of phosphate buffer and 0.1 mL of the appropriate concentration of test item formulation, solvent vehicle or 0.1 mL of appropriate positive control were incubated at 37 ± 3 °C for 20 minutes (with shaking) prior to addition of 2 mL of molten, trace amino-acid supplemented media and subsequent plating onto Vogel Bonner plates. Negative (untreated) controls were also performed on the same day as the mutation test employing the plate incorporation method. All testing for this experiment was performed in triplicate.
With Metabolic Activation
The procedure was the same as described previously except that following the addition of the test item formulation and bacterial strain culture, 0.5 mL of S9 mix was added to the tube instead of phosphate buffer, prior to incubation at 37 ± 3 °C for 20 minutes (with shaking) and addition of molten, trace amino-acid supplemented media. All testing for this experiment was performed in triplicate.
Incubation and Scoring
All of the plates were incubated at 37 ± 3 °C for between 48 and 72 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity). - Rationale for test conditions:
- The study was based on the in vitro technique described by Ames et al., (1975), Maron and Ames (1983) and Mortelmans and Zeiger (2000), in which mutagenic effects are determined by exposing mutant strains of Salmonella typhimurium to various concentrations of the test item. These Salmonella typhimurium strains have a deleted excision repair mechanism which makes them more sensitive to various mutagens and they will not grow on media which does not contain histidine. When large numbers of these organisms are exposed to a mutagen, reverse mutation to the original histidine independent form takes place. These are readily detectable due to their ability to grow on a histidine deficient medium. Using these strains of Salmonella typhimurium, revertants may be produced after exposure to a chemical mutagen which have arisen as a result of a base-pair substitution in the genetic material (miscoding) or as a frameshift mutation in which genetic material is either added or deleted. Additionally, a mutant strain of Escherichia coli (WP2uvrA) which requires tryptophan and can be reverse mutated by base substitution to tryptophan independence (Green and Muriel, 1976 and Mortelmans and Riccio, 2000) is used to complement the Salmonella strains.
Since many compounds do not exert a mutagenic effect until they have been metabolized by enzyme systems not available in the bacterial cell, the test item and the bacteria are also incubated in the presence of a liver microsomal preparation (S9-mix) prepared from rats pre treated with a mixture known to induce an elevated level of these enzymes. - Evaluation criteria:
- There are several criteria for determining a positive result. Any, one, or all of the following can be used to determine the overall result of the study:
1. A dose-related increase in mutant frequency over the dose range tested (De Serres and Shelby, 1979).
2. A reproducible increase at one or more concentrations.
3. Biological relevance against in-house historical control ranges.
4. A fold increase greater than two times the concurrent solvent control for TA100, TA98 and WP2uvrA or a three-fold increase for TA1535 and TA1537 (especially if accompanied by an out of historical range response (Cariello and Piegorsch, 1996)).
5. Statistical analysis of data as determined by UKEMS (Mahon et al., 1989).
A test item will be considered non-mutagenic (negative) in the test system if the above criteria are not met.
Although most experiments will give clear positive or negative results, in some instances the data generated will prohibit making a definite judgment about test item activity. Results of this type will be reported as equivocal. - Statistics:
- Statistical significance was confirmed by using Dunnetts Regression Analysis (* = p < 0.05) for those values that indicate statistically significant increases in the frequency of revertant colonies compared to the concurrent solvent control.
Results and discussion
Test resultsopen allclose all
- Key result
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Prior to use, the master strains were checked for characteristics, viability and spontaneous reversion rate (all were found to be satisfactory). The amino acid supplemented top agar and the S9-mix used in both experiments was shown to be sterile. The test item formulation was also shown to be sterile. These data are not given in the report.
Results for the negative controls (spontaneous mutation rates) were considered to be acceptable. These data are for concurrent untreated control plates performed on the same day as the Mutation Test.
The vehicle (dimethyl sulphoxide) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with and without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
Experiment 1 (plate incorporation):
The maximum dose level of the test item in the first experiment was selected as the OECD TG 471 recommended dose level of 5000 µg/plate.
There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix).
A test item precipitate (black and fibrous in appearance) was noted by eye at 1500 and 5000 µg/plate in the absence and presence of metabolic activation (S9-mix), respectively. This observation did not prevent the scoring of revertant colonies.
There were no significant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix).
Experiment 2 (pre-incubation):
The maximum dose level of the test item in the second experiment was the same as for Experiment 1 (5000 µg/plate).
There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix).
A test item precipitate (black and fibrous in appearance) was noted by eye at 5000 µg/plate in both the presence and absence of metabolic activation (S9-mix). This observation did not prevent the scoring of revertant colonies.
There were no significant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix).
Any other information on results incl. tables
Spontaneous Mutation Rates (Concurrent Negative Controls)
Experiment 1
Number of revertants (mean number of colonies per plate) |
|||||||||
Base-pair substitution type |
Frameshift type |
||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||
143 |
|
18 |
|
15 |
|
25 |
|
20 |
|
113 |
(130) |
26 |
(24) |
24 |
(24) |
28 |
(26) |
11 |
(15) |
133 |
|
28 |
|
33 |
|
24 |
|
13 |
|
Experiment 2
Number of revertants (mean number of colonies per plate) |
|||||||||
Base-pair substitution type |
Frameshift type |
||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||
161 |
|
19 |
|
29 |
|
23 |
|
12 |
|
146 |
(149) |
32 |
(23) |
37 |
(32) |
27 |
(26) |
17 |
(13) |
140 |
|
19 |
|
29 |
|
27 |
|
11 |
|
Test Results: Experiment 1 – Without Metabolic Activation (Plate Incorporation)
Test Period |
From: 17 July 2018 |
To: 20 July 2018 |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
128 113 120 |
(120) 7.5# |
25 30 25 |
(27) 2.9 |
27 29 27 |
(28) 1.2 |
13 15 26 |
(18) 7.0 |
11 17 10 |
(13) 3.8 |
||
1.5 µg |
132 139 119 |
(130) 10.1 |
26 25 27 |
(26) 1.0 |
25 23 33 |
(27) 5.3 |
22 23 21 |
(22) 1.0 |
10 13 15 |
(13) 2.5 |
||
5 µg |
130 129 130 |
(130) 0.6 |
31 23 23 |
(26) 4.6 |
15 31 23 |
(23) 8.0 |
10 16 17 |
(14) 3.8 |
11 18 15 |
(15) 3.5 |
||
15 µg |
133 121 120 |
(125) 7.2 |
25 26 36 |
(29) 6.1 |
27 16 19 |
(21) 5.7 |
18 18 16 |
(17) 1.2 |
19 8 22 |
(16) 7.4 |
||
50 µg |
131 122 138 |
(130) 8.0 |
27 24 26 |
(26) 1.5 |
29 27 27 |
(28) 1.2 |
22 14 19 |
(18) 4.0 |
20 13 13 |
(15) 4.0 |
||
150 µg |
121 125 129 |
(125) 4.0 |
22 24 28 |
(25) 3.1 |
23 22 40 |
(28) 10.1 |
18 19 15 |
(17) 2.1 |
15 11 11 |
(12) 2.3 |
||
500 µg |
96 121 112 |
(110) 12.7 |
25 21 30 |
(25) 4.5 |
26 24 30 |
(27) 3.1 |
26 20 28 |
(25) 4.2 |
11 7 10 |
(9) 2.1 |
||
1500 µg |
107 P 134 P 112 P |
(118) 14.4 |
27 P 26 P 26 P |
(26) 0.6 |
27 P 23 P 28 P |
(26) 2.6 |
13 P 21 P 18 P |
(17) 4.0 |
7 P 10 P 11 P |
(9) 2.1 |
||
5000 µg |
119 P 113 P 121 P |
(118) 4.2 |
31 P 21 P 24 P |
(25) 5.1 |
29 P 27 P 18 P |
(25) 5.9 |
24 P 15 P 24 P |
(21) 5.2 |
9 P 14 P 18 P |
(14) 4.5 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
||||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
||||||||
681 670 655 |
(669) 13.1 |
710 835 1023 |
(856) 157.6 |
900 864 779 |
(848) 62.1 |
159 157 146 |
(154) 7.0 |
407 332 366 |
(368) 37.6 |
|||
ENNG N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO 4-Nitroquinoline-1-oxide
9AA 9-Aminoacridine
P Test Item Precipitate
# Standard deviation
Test Results: Experiment 1 – With Metabolic Activation (Plate Incorporation)
Test Period |
From: 17 July 2018 |
To: 20 July 2018 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
152 141 145 |
(146) 5.6# |
12 13 14 |
(13) 1.0 |
35 32 33 |
(33) 1.5 |
22 18 24 |
(21) 3.1 |
15 10 10 |
(12) 2.9 |
||
1.5 µg |
134 120 142 |
(132) 11.1 |
18 8 15 |
(14) 5.1 |
47 42 37 |
(42) 5.0 |
28 30 28 |
(29) 1.2 |
12 9 9 |
(10) 1.7 |
||
5 µg |
151 133 151 |
(145) 10.4 |
10 19 16 |
(15) 4.6 |
28 31 21 |
(27) 5.1 |
23 30 29 |
(27) 3.8 |
13 16 12 |
(14) 2.1 |
||
15 µg |
126 134 132 |
(131) 4.2 |
14 11 13 |
(13) 1.5 |
35 33 33 |
(34) 1.2 |
20 25 23 |
(23) 2.5 |
15 11 14 |
(13) 2.1 |
||
50 µg |
134 132 127 |
(131) 3.6 |
13 19 5 |
(12) 7.0 |
30 27 29 |
(29) 1.5 |
24 24 32 |
(27) 4.6 |
16 12 12 |
(13) 2.3 |
||
150 µg |
141 134 130 |
(135) 5.6 |
15 8 17 |
(13) 4.7 |
31 32 29 |
(31) 1.5 |
20 25 31 |
(25) 5.5 |
18 10 12 |
(13) 4.2 |
||
500 µg |
118 128 110 |
(119) 9.0 |
8 16 9 |
(11) 4.4 |
25 45 35 |
(35) 10.0 |
15 26 28 |
(23) 7.0 |
10 15 8 |
(11) 3.6 |
||
1500 µg |
119 111 138 |
(123) 13.9 |
13 9 12 |
(11) 2.1 |
40 36 31 |
(36) 4.5 |
30 26 24 |
(27) 3.1 |
13 10 15 |
(13) 2.5 |
||
5000 µg |
120 P 111 P 107 P |
(113) 6.7 |
10 P 8 P 12 P |
(10) 2.0 |
33 P 32 P 38 P |
(34) 3.2 |
28 P 29 P 26 P |
(28) 1.5 |
13 P 16 P 12 P |
(14) 2.1 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
1559 1657 2216 |
(1811) 354.4 |
295 331 310 |
(312) 18.1 |
226 220 241 |
(229) 10.8 |
151 121 131 |
(134) 15.3 |
306 353 395 |
(351) 44.5 |
BP Benzo(a)pyrene
2AA 2-Aminoanthracene
P Test item precipitate
# Standard deviation
Test Results: Experiment 2 – Without Metabolic Activation (Pre-Incubation)
Test Period |
From: 20 July 2018 |
To: 23 July 2018 |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
154 123 153 |
(143) 17.6# |
22 15 19 |
(19) 3.5 |
21 38 34 |
(31) 8.9 |
29 16 24 |
(23) 6.6 |
11 15 6 |
(11) 4.5 |
||
15 µg |
137 158 157 |
(151) 11.8 |
23 18 20 |
(20) 2.5 |
28 27 38 |
(31) 6.1 |
27 28 13 |
(23) 8.4 |
17 16 14 |
(16) 1.5 |
||
50 µg |
154 149 149 |
(151) 2.9 |
22 19 23 |
(21) 2.1 |
33 28 24 |
(28) 4.5 |
36 32 27 |
(32) 4.5 |
15 13 24 |
(17) 5.9 |
||
150 µg |
141 144 152 |
(146) 5.7 |
16 18 14 |
(16) 2.0 |
30 36 22 |
(29) 7.0 |
24 19 26 |
(23) 3.6 |
12 11 14 |
(12) 1.5 |
||
500 µg |
129 154 150 |
(144) 13.4 |
27 20 26 |
(24) 3.8 |
32 29 30 |
(30) 1.5 |
19 24 22 |
(22) 2.5 |
15 17 23 |
(18) 4.2 |
||
1500 µg |
136 141 135 |
(137) 3.2 |
21 31 23 |
(25) 5.3 |
34 34 32 |
(33) 1.2 |
32 21 26 |
(26) 5.5 |
18 14 7 |
(13) 5.6 |
||
5000 µg |
138 P 150 P 137 P |
(142) 7.2 |
31 P 30 P 17 P |
(26) 7.8 |
39 P 30 P 33 P |
(34) 4.6 |
20 P 22 P 24 P |
(22) 2.0 |
17 P 23 P 9 P |
(16) 7.0 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
||||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
||||||||
987 864 946 |
(932) 62.6 |
1013 986 1034 |
(1011) 24.1 |
1104 1060 1124 |
(1096) 32.7 |
262 281 280 |
(274) 10.7 |
483 486 510 |
(493) 14.8 |
|||
ENNG N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO 4-Nitroquinoline-1-oxide
9AA 9-Aminoacridine
P Test item precipitate
# Standard deviation
Test Results: Experiment 2 – With Metabolic Activation (Pre-Incubation)
Test Period |
From: 20 July 2018 |
To: 23 July 2018 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
152 129 149 |
(143) 12.5# |
11 14 17 |
(14) 3.0 |
47 31 38 |
(39) 8.0 |
28 29 37 |
(31) 4.9 |
16 25 14 |
(18) 5.9 |
||
15 µg |
134 149 148 |
(144) 8.4 |
8 18 20 |
(15) 6.4 |
36 39 35 |
(37) 2.1 |
35 24 34 |
(31) 6.1 |
15 11 20 |
(15) 4.5 |
||
50 µg |
134 129 119 |
(127) 7.6 |
13 18 17 |
(16) 2.6 |
38 32 44 |
(38) 6.0 |
32 40 26 |
(33) 7.0 |
9 22 18 |
(16) 6.7 |
||
150 µg |
132 121 128 |
(127) 5.6 |
17 14 18 |
(16) 2.1 |
35 42 37 |
(38) 3.6 |
28 29 31 |
(29) 1.5 |
16 12 13 |
(14) 2.1 |
||
500 µg |
132 124 111 |
(122) 10.6 |
14 18 16 |
(16) 2.0 |
37 40 42 |
(40) 2.5 |
30 28 23 |
(27) 3.6 |
23 19 15 |
(19) 4.0 |
||
1500 µg |
134 127 155 |
(139) 14.6 |
28 15 18 |
(20) 6.8 |
41 41 36 |
(39) 2.9 |
27 36 31 |
(31) 4.5 |
22 20 22 |
(21) 1.2 |
||
5000 µg |
142 P 126 P 180 P |
(149) 27.7 |
16 P 22 P 12 P |
(17) 5.0 |
36 P 55 P 37 P |
(43) 10.7 |
17 P 29 P 30 P |
(25) 7.2 |
8 P 14 P 32 P |
(18) 12.5 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
2346 2185 2031 |
(2187) 157.5 |
386 426 411 |
(408) 20.2 |
144 151 147 |
(147) 3.5 |
87 120 145 |
(117) 29.1 |
386 314 337 |
(346) 36.8 |
|||
BP Benzo(a)pyrene
2AA 2-Aminoanthracene
P Test item precipitate
# Standard deviation
Applicant's summary and conclusion
- Conclusions:
- In this Reverse Mutation Assay ‘Ames Test’ using strains of Salmonella typhimurium and Escherichia coli (OECD TG 471) the test item Reaction mass of crystalline magnesium silicate and crystalline silicon and synthetic amorphous silicon dioxide did not induce an increase in the frequency of revertant colonies at any of the dose levels used either with or without metabolic activation (S9-mix). Under the conditions of this test Reaction mass of crystalline magnesium silicate and crystalline silicon and synthetic amorphous silicon dioxide was considered to be non-mutagenic.
- Executive summary:
Introduction
The test method was designed to be compatible with the guidelines for bacterial mutagenicity testing published by the major Japanese Regulatory Authorities including METI, MHLW and MAFF, the OECD Guidelines for Testing of Chemicals No. 471 "Bacterial Reverse Mutation Test", Method B13/14 of Commission Regulation (EC) number 440/2008 of 30 May 2008, the ICH S2(R1)guideline adopted June 2012 (ICH S2(R1) Federal Register. Adopted 2012; 77:33748-33749)and the USA, EPA OCSPP harmonized guideline - Bacterial Reverse Mutation Test.
Methods
Salmonella typhimurium strains TA1535, TA1537, TA98 and TA100 and Escherichia coli strain WP2uvrA were treated with suspensions of the test item using both the Ames plate incorporation and pre-incubation methods at up to eight dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (10% liver S9 in standard co-factors). The dose range for Experiment 1 (plate incorporation) was based on OECD TG 471 and was 1.5 to 5000 mg/plate. The experiment was repeated on a separate day (pre-incubation method) using fresh cultures of the bacterial strains and fresh test item formulations. The dose range was amended following the results of Experiment 1 and was 15 to 5000 µg/plate. Six test item concentrations per bacterial strain were selected in Experiment 2 in order to achieve both four non‑toxic dose levels and the potential toxicity of the test item following the change in test methodology.
Results
The vehicle (dimethyl sulphoxide) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with and without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The maximum dose level of the test item in the first experiment was selected as the OECD TG 471 recommended dose level of 5000 µg/plate. There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the first mutation test (plate incorporation method). A test item precipitate (black and fibrous in appearance) was noted by eye at 1500 and 5000 mg/plate in both the presence and absence of metabolic activation (S9-mix), respectively. This observation did not prevent the scoring of revertant colonies.
Based on the results of Experiment 1, the same maximum dose level (5000 µg/plate) was employed in the second mutation test (pre-incubation method). Similarly, there was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix). A test item precipitate (black and fibrous in appearance) was by eye at 5000 mg/plate in both the presence and absence of metabolic activation (S9-mix). This observation did not prevent the scoring of revertant colonies.
There were no significant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 1 (plate incorporation method).
Similarly, no significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 2 (pre‑incubation method).
Conclusion
Reaction mass of crystalline magnesium silicate and crystalline silicon and synthetic amorphous silicon dioxide was considered to be non-mutagenic under the conditions of this test.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.